Corixa publishes Phase III Bexxar data

CRXA said that in a Phase III study, its Bexxar tositumomab achieved a partial or complete response (CR) in 65% of patients with chemotherapy refractory non-Hodgkin's lymphoma (NHL), compared to a 28% response rate from the patient's last chemotherapy agent. Also, 20% of Bexxar patients had a CR compared to 3% after treatment with the previous agent. In these patients, mean response duration had not been reached, and nine of 12 patients with CRs have ongoing responses of 32.3-47.4 months at time of last data analysis. ...